United StatesA generic version of the allergy medication Zyrtec, produced by Unique Pharmaceutical Laboratories, is being recalled in the United States due to potential cross-contamination with ranitidine, a heartburn drug. The recall was initiated after a pharmacy technician noticed a red dot on some cetirizine hydrochloride tablets and discoloration on others during the counting and bottling process. The FDA warns that individuals hypersensitive to ranitidine ingredients might face serious side effects such as low blood pressure, breathing difficulties, and loss of consciousness. No adverse events have been reported yet. Affected products include 100-tablet bottles with specific lot numbers, set to expire in October 2028. Consumers are advised to contact Rising Pharma Holdings for returns and consult their healthcare providers if they experienced issues.
Bias read (Center): The article provides factual information about a product recall without showing any ideological bias. It presents the situation objectively, citing the FDA's findings and providing necessary details for affected consumers.
Why factuality (95): The article accurately reflects the FDA recall notice, mentioning the company, product type, reason for recall (cross contamination with ranitidine), affected lot numbers, and expiration dates. It also includes the risk statement and consumer contact information. However, it refers to the product as
Why objectivity (88): The tone remains neutral and informative, presenting facts from the FDA notice without bias. However, the article uses phrases like 'may have been mixed with' which introduces uncertainty not present in the original document, potentially influencing reader perception.
